NCT07012746View on ClinicalTrials.gov

A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 7, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Age Related Hearing LossDeafness
Interventions
DRUG

TJ0113 capsules

Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .

DRUG

Placebo capsules

Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .

Trial Locations (1)

200031

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Hangzhou PhecdaMed Co., Ltd.

INDUSTRY

lead

Yilai Shu

OTHER

NCT07012746 - A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss | Biotech Hunter | Biotech Hunter